Current management of amaurosis fugax. The Amaurosis Fugax Study Group.
We present a consensus on the pathophysiology, etiology, diagnosis, and treatment of amaurosis fugax. The phenomenon is defined and described, and the roles that extracranial and ocular vascular diseases play are discussed. Nonvascular ophthalmic and neurologic disorders that can be confused with amaurosis fugax are listed, and an algorithm for evaluation (which includes ophthalmic examination, laboratory studies, and noninvasive carotid artery studies) is given. Treatment of atherosclerosis, carotid artery disease, and other causes of amaurosis fugax are also discussed.
D001241:Aspirin / Q000627:therapeutic use; D001766:Blindness / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D002339:Carotid Arteries / Q000601:surgery; D002340:Carotid Artery Diseases / Q000150:complications; D002561:Cerebrovascular Disorders / Q000150:complications*; D003251:Constriction, Pathologic; D003937:Diagnosis, Differential; D004691:Endarterectomy; D006801:Humans; D009626:Terminology as Topic; D015349:Vision, Monocular
D001241:Aspirin